Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

People with acne have more CD4+ immune cells in their skin than healthy people.

Alopecia areata patients have higher levels of certain immune receptors, suggesting new treatment possibilities.

Recombinant cytokine therapy can cause skin reactions ranging from mild to severe.

γδ T cells help control tissue scarring and blood vessel growth in response to foreign objects.

Trichohyalin in hair can trigger immune attacks in alopecia areata.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

HPV8 E6 gene causes growth of certain skin stem cells.

Removing Ctip2 in skin cells causes skin inflammation similar to atopic dermatitis.

Targeting CD169+ skin macrophages may help treat psoriasis.

Type-2 immunity may influence skin diseases and could be targeted for treatment.

BST2 protein and certain T cells increase in early alopecia areata.

Relatives of lupus patients show signs of immune system activity but not full-blown lupus.

Activin increases skin tumor formation, skin Tregs help hair growth, lymph-node removal doesn't improve melanoma survival, cells can revert to stem cells in wound healing, and skin bacteria produce peptides that may treat infections.

Farudodstat can prevent hair follicle immune damage linked to alopecia areata.

The new skin-targeted COVID-19 vaccine creates strong immune responses and could improve vaccination methods.

Alopecia areata involves both innate and adaptive immunity, with specific genes linked to the disease.

Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.

COVID-19 vaccination may trigger recurrence of cutaneous T-cell lymphoma in some patients.

Interferon, especially alfa interferon, is an effective treatment for cutaneous T-cell lymphoma with manageable side effects.

CD28 is a promising target for treating alopecia areata with belatacept.

CD28 is a promising target for treating alopecia areata with belatacept.

Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.

Six months after COVID-19, most patients still had autoantibodies.

Stem cell vesicles reduced eczema symptoms in mice safely.

ILC1-like cells can cause alopecia areata by themselves.

HPV8 causes hair follicle stem cells to grow, leading to skin lesions.

Alopecia areata involves specific immune cells, offering potential treatment targets.

Enhancing immune response can improve cancer treatment effectiveness.